Drug intelligence / Profile preview

DR5 CAR-T

Development stage: Phase 2
Lead developer: BinDeBio
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

DR5 CAR-T is a Chimeric Antigen Receptor (CAR) T-cell immunotherapy developed by Shenzhen BinDeBio Ltd. It involves engineering a patient's T-cells to express a CAR that specifically recognizes and binds to Death Receptor 5 (DR5) on the surface of cancer cells. This binding is intended to activate the CAR-T cells, leading to the destruction of DR5-expressing tumor cells. The therapy is being investigated for the treatment of solid malignancies, with patients receiving pre-treatment with cyclophosphamide or fludarabine before CAR-T cell infusion.

Targets

TNFRSF10B (DR5)

Beyond the preview

Go deeper on DR5 CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DR5 CAR-T.

Explore the full profile